- Tel: 858.663.9055
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Lymphocyte Marker Antibody detects proteins expressed on lymphocytes, the adaptive immune cells that include B cells, T cells, and natural killer (NK) cells. Lymphocytes play central roles in antibody production, cytotoxic defense, immune memory, and regulation of immune tolerance. Because of their diverse functions and phenotypes, reliable markers are critical for distinguishing lymphocyte subsets and tracking their activity in health and disease.
Common targets for Lymphocyte Marker Antibodies include CD3, CD4, and CD8 (defining T cell subsets), CD19 and CD20 (B cells), and CD56 (NK cells). Additional markers such as PD-1, CTLA-4, and FOXP3 are used to study regulatory T cells and immune checkpoint pathways. The Lymphocyte Marker Antibody is thus indispensable for immunology, oncology, infectious disease, and clinical pathology.
Because lymphocytes are involved in nearly every aspect of immune defense and dysfunction, Lymphocyte Marker Antibodies are widely applied across basic research, translational studies, and clinical applications.
NSJ Bioreagents provides Lymphocyte Marker Antibodies validated for immunohistochemistry, immunofluorescence, flow cytometry, western blotting, and ELISA. Each Lymphocyte Marker Antibody is rigorously tested for specificity to lymphocyte proteins, ensuring minimal cross-reactivity with myeloid or stromal markers.
By choosing a Lymphocyte Marker Antibody from NSJ Bioreagents, scientists gain reagents optimized for reproducibility and clarity. Our antibodies provide strong staining in tissue sections, sharp population discrimination in flow cytometry, and reliable protein detection in biochemical assays. With comprehensive datasheets, recommended positive controls, and application guidance, NSJ Bioreagents ensures that Lymphocyte Marker Antibodies provide robust results across both discovery and clinical studies.
The Lymphocyte Marker Antibody has broad applications reflecting the diversity of lymphocyte biology.
Lymphocyte Marker Antibodies identify T cell subsets critical for adaptive immunity.
The Lymphocyte Marker Antibody is used to quantify B cells during antibody responses.
Researchers employ Lymphocyte Marker Antibodies to track NK cells in innate defense.
Lymphocyte Marker Antibodies detect autoreactive lymphocytes in lupus, multiple sclerosis, and type 1 diabetes.
The Lymphocyte Marker Antibody is used to measure regulatory T cells that maintain tolerance.
Researchers apply Lymphocyte Marker Antibodies to assess lymphocyte-driven inflammation in chronic disease.
Tumor-infiltrating lymphocytes (TILs) are identified using Lymphocyte Marker Antibodies.
The Lymphocyte Marker Antibody supports studies of checkpoint proteins PD-1 and CTLA-4.
Lymphocyte Marker Antibodies are applied to evaluate biomarkers predicting immunotherapy success.
Lymphocyte Marker Antibodies help monitor CD4+ T cell loss in HIV infection.
The Lymphocyte Marker Antibody is used to assess immune reconstitution after antiviral therapy.
Lymphocyte Marker Antibodies support vaccine trials by quantifying antigen-specific lymphocytes.
Lymphocyte Marker Antibodies are applied in graft rejection studies.
The Lymphocyte Marker Antibody helps evaluate immunosuppressive drug effects on T and B cells.
Researchers employ Lymphocyte Marker Antibodies to clarify immune tolerance mechanisms.
Lymphocyte Marker Antibodies track inflammation in atherosclerosis and obesity.
The Lymphocyte Marker Antibody highlights T cell–mediated contributions to metabolic dysfunction.
Lymphocyte Marker Antibodies validate biomarkers in clinical trials of immunotherapies.
The Lymphocyte Marker Antibody is used to evaluate pharmacodynamic effects of drugs targeting lymphocytes.
Lymphocyte Marker Antibodies support regenerative medicine by assessing immune compatibility of grafts.
Lymphocytes orchestrate adaptive immunity and influence nearly every area of human health. The Lymphocyte Marker Antibody provides the resolution to analyze these essential cells, while Lymphocyte Marker Antibodies more broadly empower research across immunology, oncology, infectious disease, and translational medicine.
In basic research, Lymphocyte Marker Antibodies clarify immune mechanisms underlying defense and tolerance. In clinical pathology, the Lymphocyte Marker Antibody supports diagnosis of lymphoid malignancies and immune deficiencies. In therapeutics, Lymphocyte Marker Antibodies provide biomarkers for precision immunotherapy.
Clinically, lymphocyte markers are used to guide diagnosis, monitor progression, and predict treatment outcomes in cancer, autoimmunity, and infection. By ensuring accurate measurement of lymphocyte activity, the Lymphocyte Marker Antibody bridges molecular biology with patient care, advancing both discovery and therapeutic innovation.
Lymphocytes are central to immunity, memory, and regulation. The Lymphocyte Marker Antibody equips scientists and clinicians with a precise tool for detecting lymphocyte proteins, while Lymphocyte Marker Antibodies more broadly support progress in immunology, oncology, infectious disease, and translational research. By connecting fundamental biology with clinical application, these antibodies remain indispensable for advancing immune science and improving human health.
IHC staining of FFPE human tonsil tissue with CD74 antibody (clone LN-2).
| ||
![]() |
| ||
![]() |
| ||
![]() |